Screener
Generate Biomedicines, Inc. GENB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
FAQ
- What is Generate Biomedicines, Inc.'s cash & equivalents?
- Generate Biomedicines, Inc. (GENB) reported cash & equivalents of $135.36M in Q2 2026.
- How has Generate Biomedicines, Inc.'s cash & equivalents changed year-over-year?
- Generate Biomedicines, Inc.'s cash & equivalents decreased by 12.3% year-over-year, from $154.27M to $135.36M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Generate Biomedicines, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude